Skip to Content

EOM Pharmaceutical Holdings Inc IMUC

Morningstar Rating
$0.20 +0.02 (12.16%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IMUC is trading at a 66% discount.
Price
$0.20
Fair Value
$1.20
Uncertainty
Extreme
1-Star Price
$57.16
5-Star Price
$6.53
Economic Moat
Pxp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMUC is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.18
Day Range
$0.200.20
52-Week Range
$0.110.40
Bid/Ask
$0.00 / $0.29
Market Cap
$22.42 Mil
Volume/Avg
212 / 3,731

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve the lives of patients suffering from debilitating and sometimes deadly diseases. Its pipeline includes compound EOM613, an investigational novel dynamically dual-acting immunomodulator. EOM613 is a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad-spectrum cytokine effects.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
4

Valuation

Metric
IMUC
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
IMUC

Financial Strength

Metric
IMUC
Quick Ratio
8.31
Current Ratio
9.53
Interest Coverage
Quick Ratio
IMUC

Profitability

Metric
IMUC
Return on Assets (Normalized)
−97.59%
Return on Equity (Normalized)
−324.91%
Return on Invested Capital (Normalized)
−323.89%
Return on Assets
IMUC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMthwnmzrkHwrz$550.4 Bil
VRTX
Vertex Pharmaceuticals IncSvbjwszWyypjk$101.7 Bil
REGN
Regeneron Pharmaceuticals IncKmvbzkzpGzclm$98.1 Bil
MRNA
Moderna IncJnfkzwqTqnt$38.8 Bil
ARGX
argenx SE ADRRbftqplRzsh$21.7 Bil
BNTX
BioNTech SE ADRPrhswzyjYshwc$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncMlgskgvwxTrdzyp$18.4 Bil
BMRN
Biomarin Pharmaceutical IncXxvtqymfPmhgzg$17.1 Bil
RPRX
Royalty Pharma PLC Class ABqxvljmkGxhhym$12.5 Bil
INCY
Incyte CorpMytzvmnjsCzbwf$11.9 Bil

Sponsor Center